AU2021275224A1 - Methods of treating acute respiratory distress syndrome with activators of Tie-2 - Google Patents

Methods of treating acute respiratory distress syndrome with activators of Tie-2 Download PDF

Info

Publication number
AU2021275224A1
AU2021275224A1 AU2021275224A AU2021275224A AU2021275224A1 AU 2021275224 A1 AU2021275224 A1 AU 2021275224A1 AU 2021275224 A AU2021275224 A AU 2021275224A AU 2021275224 A AU2021275224 A AU 2021275224A AU 2021275224 A1 AU2021275224 A1 AU 2021275224A1
Authority
AU
Australia
Prior art keywords
administration
subject
substituted
group
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021275224A
Other languages
English (en)
Inventor
Kevin Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals Inc
Original Assignee
Eyepoint Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Inc filed Critical Eyepoint Pharmaceuticals Inc
Publication of AU2021275224A1 publication Critical patent/AU2021275224A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021275224A 2020-05-21 2021-05-20 Methods of treating acute respiratory distress syndrome with activators of Tie-2 Pending AU2021275224A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063028317P 2020-05-21 2020-05-21
US63/028,317 2020-05-21
PCT/US2021/033495 WO2021236985A1 (en) 2020-05-21 2021-05-20 Methods of treating acute respiratory distress syndrome with activators of tie-2

Publications (1)

Publication Number Publication Date
AU2021275224A1 true AU2021275224A1 (en) 2022-10-13

Family

ID=78707586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021275224A Pending AU2021275224A1 (en) 2020-05-21 2021-05-20 Methods of treating acute respiratory distress syndrome with activators of Tie-2

Country Status (7)

Country Link
US (1) US12544362B2 (https=)
EP (1) EP4153237A4 (https=)
JP (1) JP7783834B2 (https=)
CN (1) CN115666651A (https=)
AU (1) AU2021275224A1 (https=)
CA (1) CA3177415A1 (https=)
WO (1) WO2021236985A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2195958C1 (ru) 2002-02-19 2003-01-10 Центральный научно-исследовательский институт туберкулеза РАМН Способ лечения синдрома острого повреждения легких после расширенных оперативных вмешательств
WO2004075838A2 (en) * 2003-02-21 2004-09-10 Rikshospitalet-Radiumhospitalet Hf Method and compositions for the treatment of meconium aspiration syndrome
WO2005034929A2 (en) 2003-10-10 2005-04-21 Fibrogen, Inc. Tissue remodeling and vascularization
WO2007084136A2 (en) 2006-01-23 2007-07-26 Ony, Inc. Treatment of acute respiratory distress syndrome
DK2385763T3 (en) * 2009-01-12 2018-07-16 Aerpio Therapeutics Inc METHODS OF TREATING VASCULAR LEAK SYNDROME
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
CA2909080C (en) * 2013-04-11 2022-07-26 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
US9381212B2 (en) * 2014-01-10 2016-07-05 Mallinckrodt Hospital Products IP Limited Methods of using inhaled nitric oxide gas for treatment of acute respiratory distress syndrome in children
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
CA3137138A1 (en) * 2019-04-18 2020-10-22 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of tie-2

Also Published As

Publication number Publication date
EP4153237A1 (en) 2023-03-29
WO2021236985A1 (en) 2021-11-25
JP7783834B2 (ja) 2025-12-10
EP4153237A4 (en) 2024-07-03
US20240299367A1 (en) 2024-09-12
CN115666651A (zh) 2023-01-31
CA3177415A1 (en) 2021-11-25
JP2023526790A (ja) 2023-06-23
US12544362B2 (en) 2026-02-10

Similar Documents

Publication Publication Date Title
US11324708B1 (en) Niclosamide formulations for treating disease
US11364227B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
WO2021195211A1 (en) Quinoline compounds for treating respiratory disorders and viral infections
US20230129866A1 (en) Methods of treating respiratory disease with deupirfenidone
US20200352914A1 (en) Methods of treating hypertension with activators of tie-2
JP2017507949A (ja) マトリックスメタロプロテイナーゼ９に対する抗体およびその使用の方法
US12544362B2 (en) Methods of treating acute respiratory distress syndrome with activators of Tie-2
US20230125415A1 (en) Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
KR20230018474A (ko) 급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법
US20230151093A1 (en) Methods of treating immune mediated pulmonary injury
WO2024038186A1 (en) Treatment of acute respiratory failure
US20230357418A1 (en) Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
US20240269112A1 (en) Injectable melatonin composition for the treatment of viral diseases
WO2021194860A1 (en) Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
US20250025450A1 (en) Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
US20260041656A1 (en) Treating pulmonary hypertension based on novel biomarker
US20250205268A1 (en) Treatment of viruses with antiviral nucleosides
US20240025991A1 (en) Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
Howells Oesophagectomy as a model of the Acute Respiratory Distress Syndrome
Gavra et al. Manuscript# 4: Pharmacokinetics and pharmacodynamics of nebulized and intratracheal milrinone in a hypercapnic swine pulmonary hypertension model.
Van Heerden Inhaled Aerosolised Prostacyclin as a Selective Pulmonary Vasodilator
JPWO2005056009A1 (ja) 肺疾患治療剤

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO EYEPOINT, INC.